COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study
In conclusion, patients with NSCLC are at high risk for VTE, especially those with adenocarcinoma, metastatic disease and when treated with immunotherapy. Compared to Khorana RAM, COMPASS-CAT RAM was better in identifying more patients in high-risk group, with higher VTE rate.
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Thrombosis